( August 19, 2026, 15:53 GMT | Official Statement) -- MLex Summary: Plaintiffs opposed a motion for judgment filed by Supernus Pharmaceuticals, Britannia Pharmaceuticals and US WorldMeds Partners in a US case accusing them of engaging in a conspiracy to restrain generic competition for branded Apokyn. “After devoting ten pages to plaintiffs’ purported business strategy, defendants’ anticompetitive conduct—the subject of this lawsuit—received just three pages, sanitized beyond recognition. But revisionist storytelling cannot obscure the record: Defendants agreed to ‘block and build obstacles’ to generic competition; described their scheme as an effort to ‘create multiple generic barriers to entrance;’ and admitted they acted ‘to help mitigate the risk’ of ‘a generic entrant,’ ‘prevent[] access by competitors,’ and render generic cartridges nonviable and ‘obsolete,’” they said.See attached files. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.